Ontario Institute for Cancer Research — CureCurrent

Published trials16

Recruiting shown2

Roles1

SourceClinicalTrials.gov

Clinical trials

16 shown

Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O)NCT05403177 · collaborator · 2022-06-23

Using ctDNA to Detect Minimal Residual Disease After Lung Cancer ResectionNCT05254782 · collaborator · 2021-07-06

--SuPERIOR Trial--NCT06191250 · collaborator · 2024-09-28

PD-1 +/- IL-4 Inhibition in ER+ Breast CancerNCT05967884 · collaborator · 2023-08-04

......SMARTEST Trial......NCT05380713 · collaborator · 2022-05-03

A Phase II Window of Opportunity Trial of PRMT5 Inhibitor, GSK3326595, in Early Stage Breast CancerNCT04676516 · collaborator · 2021-06-08

INVINCIBLE TRIAL: Intratumoral INT230-6 in Breast CancerNCT04781725 · collaborator · 2021-03-25

Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of ExposureNCT04442048 · collaborator · 2020-10-01

Tracking Peripheral Blood Mononuclear Cells With Fluorine MRINCT02921373 · collaborator · 2019-07-01

CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast CancerNCT03568422 · collaborator · 2019-02-05

ACTIVE_NOT_RECRUITING

Advanced Prostate Imaging of Recurrent Cancer After RadiotherapyNCT02793284 · collaborator · 2017-01-09

PRostate Evaluation for Clinically Important Disease: MRI vs Standard Evaluation ProceduresNCT02936258 · collaborator · 2016-11-01

Stereotactic Image-Guided Neoadjuvant Ablative Radiation Then LumpectomyNCT02212860 · collaborator · 2015-04-27

18F-FCH PET/MRI to Assess Tumor Response in Castration Resistant Prostate CancerNCT02121600 · collaborator · 2014-09-01

Feasibility Study of Genomic Profiling Methods and Timing in Tumor SamplesNCT01703585 · collaborator · 2012-10-04

Active Surveillance Magnetic Resonance Imaging StudyNCT01354171 · collaborator · 2011-11-01

Sponsor roles

collaborator16

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.